NASDAQ: NAKANakamoto Inc Stock
$4.68+0.37 (+8.58%)
Updated Jun 8, 2026
NAKA Price
$4.68
Fair Value Price
N/A
Market Cap
$81.44M
52 Week Low
$4.13
52 Week High
$808.00
P/E
-0.69x
P/B
0.22x
P/S
35.87x
PEG
N/A
Dividend Yield
N/A
Revenue
$3.92M
Earnings
-$289.97M
Gross Margin
94.3%
Operating Margin
-7,110.12%
Profit Margin
-7,397.8%
Debt to Equity
0.69
Operating Cash Flow
-$46M
Beta
2.59
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
NAKA Overview
Specializing in the development and financial backing of a global array of Bitcoin-centric businesses, Nakamoto Inc. also provides crucial commercial and financial infrastructure for capital markets. The company, founded in 2019, was originally known as Kindly MD, Inc. but rebranded as Nakamoto Inc. in January 2026. It is headquartered in Nashville, Tennessee.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine NAKA's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -4.50% per year. Learn More
Zen Rating Component Grades
F
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Care Facility
Industry Rating
A
NAKA
Ranked#39 of 40
Ranked#39 of 40
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $22.47 | A | |
| $6.64 | A | |
| $31.04 | A |
Be the first to know about important NAKA news, forecast changes, insider trades & much more!
NAKA News
Overview
Due Diligence Score
–
Industry Average (29)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how NAKA scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NAKA is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NAKA is good value based on its book value relative to its share price (0.22x), compared to the US Medical Care Facilities industry average (4.55x)
P/B vs Industry Valuation
NAKA is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more NAKA due diligence checks available for Premium users.
Valuation
NAKA price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.69x
Industry
14.33x
Market
14.72x
NAKA price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.22x
Industry
4.55x
NAKA is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NAKA's financial health
Profit margin
Revenue
$2.7M
Net Income
-$238.8M
Profit Margin
-8,916.2%
NAKA's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
NAKA's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$620.8M
Liabilities
$253.7M
Debt to equity
0.69
NAKA's short-term liabilities ($251.70M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NAKA's short-term assets ($63.42M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NAKA's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$23.3M
Investing
$36.6M
Financing
-$561.0k
NAKA's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
NAKA vs Medical Care Facility Stocks
Nakamoto Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.